Castle Biosciences vs NeoGenomics
CSTL and NEO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSTL and NEO compare
NeoGenomics is the larger company, worth 2.0 times as much as Castle Biosciences ($2.0B against $1.0B).
NeoGenomics grew revenue faster over the last twelve months (11.1% versus 9.8% for Castle Biosciences).
NeoGenomics keeps more of each dollar of sales as profit, with a net margin of −4.1% compared with −6.1% at Castle Biosciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSTL | NEO |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $2.0B |
| Share price | $32.75 | $15.41 |
| Change, 1 year | −4.0% | 53.9% |
| Change, 5 years | −24.0% | −58.0% |
| Beta (5Y) | 0.69 | 0.84 |
| Employees | 883 | 2,500 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× | 2.5× (better) |
| P/B | 2.1× (better) | 2.5× |
| P/FCF | 252× | – |
| FCF yield | 0.40% (better) | −1.4% |
| Fair value | $34.29 | $19.92 |
| Margin of safety | 4.5% | 22.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.8% | 11.1% (better) |
| Revenue growth, 5Y average | 40.6% (better) | 10.4% |
| Profitability | ||
| Gross margin | 77.1% (better) | 44.8% |
| Operating margin | −7.4% | −6.3% (better) |
| Net margin | −6.1% | −4.1% (better) |
| FCF margin | 1.1% (better) | −3.6% |
| Return on equity | −4.9% | −3.9% (better) |
| Return on invested capital | −11.1% | −4.6% (better) |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.47 |
| Interest coverage | −51.2× | −15.2× (better) |
| Current ratio | 5.28 (better) | 3.53 |
| Altman Z-score | 6.44 (better) | 2.32 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −0.02% |
| Shareholder yield | 0.00% (better) | −0.02% |
| Ownership | ||
| Held by institutions | 89.5% | 112% |
| Held by insiders | 1.9% | 1.5% |
| Insider net buying, 12 months | −$18.4M | −$717K (better) |
| Short interest, % of float | 7.0% | 10.3% |
Go deeper
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
- NEO stock overview
- NEO income statement
- NEO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.